company background image
JAGSNPHARM logo

Jagsonpal Pharmaceuticals NSEI:JAGSNPHARM Stok Raporu

Son Fiyat

₹592.60

Piyasa Değeri

₹15.7b

7D

11.1%

1Y

53.5%

Güncellenmiş

21 Nov, 2024

Veri

Şirket Finansalları

Jagsonpal Pharmaceuticals Limited

NSEI:JAGSNPHARM Stok Raporu

Piyasa değeri: ₹15.7b

JAGSNPHARM Stoklara Genel Bakış

Jagsonpal Pharmaceuticals Limited, Hindistan'da ve uluslararası alanda farmasötik ürünlerin ve aktif farmasötik bileşenlerin üretimi, satışı ve ticareti ile uğraşmaktadır. Daha fazla detay

JAGSNPHARM temel anali̇z
Kar Tanesi Skoru
Değerleme0/6
Gelecekteki Büyüme0/6
Geçmiş Performans2/6
Finansal Sağlık6/6
Temettüler4/6

Jagsonpal Pharmaceuticals Limited Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Jagsonpal Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı₹592.60
52 Haftanın En Yüksek Seviyesi₹628.85
52 Haftanın En Düşük Seviyesi₹273.60
Beta1.05
11 Aylık Değişim29.90%
3 Aylık Değişim56.57%
1 Yıllık Değişim53.48%
33 Yıllık Değişim284.56%
5 Yıllık Değişim2,179.23%
Halka arzdan bu yana değişim-11.95%

Son Haberler & Güncellemeler

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Recent updates

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06
Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29
Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13
A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05
Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21
Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08
The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21
Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Hissedar Getirileri

JAGSNPHARMIN PharmaceuticalsIN Pazar
7D11.1%-0.2%0.3%
1Y53.5%40.5%27.3%

Getiri vs. Endüstri: JAGSNPHARM geçen yıl % 40.5 oranında getiri sağlayan Indian Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: JAGSNPHARM geçen yıl % 27.3 oranında getiri sağlayan Indian Piyasasını aştı.

Fiyat Oynaklığı

Is JAGSNPHARM's price volatile compared to industry and market?
JAGSNPHARM volatility
JAGSNPHARM Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market4.0%

İstikrarlı Hisse Senedi Fiyatı: JAGSNPHARM hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: JAGSNPHARM 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala Indian hisselerinin %75'inden yüksek.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
19781,025Manish Guptawww.jagsonpal.com

Jagsonpal Pharmaceuticals Limited, Hindistan'da ve uluslararası alanda farmasötik ürünlerin ve aktif farmasötik bileşenlerin üretimi, satışı ve ticareti ile uğraşmaktadır. Jinekoloji, ortopedi, dermatoloji ve pediatri alanlarında farmasötik formülasyonlar ve ürünler sunmaktadır. Şirket, tablet, yumuşak jel, enjeksiyon, kapsül ve şurup şeklinde ilaçlar sağlamaktadır.

Jagsonpal Pharmaceuticals Limited Temel Bilgiler Özeti

Jagsonpal Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
JAGSNPHARM temel i̇stati̇sti̇kler
Piyasa değeri₹15.71b
Kazançlar(TTM)₹243.00m
Gelir(TTM)₹2.27b

64.7x

F/K Oranı

6.9x

P/S Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
JAGSNPHARM gelir tablosu (TTM)
Gelir₹2.27b
Gelir Maliyeti₹864.72m
Brüt Kâr₹1.40b
Diğer Giderler₹1.16b
Kazançlar₹243.00m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)9.16
Brüt Marj61.88%
Net Kâr Marjı10.71%
Borç/Özkaynak Oranı0%

JAGSNPHARM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.8%

Mevcut Temettü Verimi

59%

Ödeme Oranı